ArticleBMC complementary medicine and therapies2025
Analysis of suspected serious adverse drug reactions reported with traditional medicines from the United Nations Asia region in WHO vigibase.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraditional medicines (TMs) are not regulated like conventional drugs in many countries, and they are often perceived as safe, which leads to large-scale self-medication. There is limited safety information available for TMs. Thus, including them in pharmacovigilance systems is crucial for systematically gathering and evaluating adverse drug reactions (ADRs) to enhance safety and prevent harm with their use. Therefore, this study analyzed the pattern of serious suspected ADRs reported with TMs to the WHO Uppsala Monitoring Center.
methodsIndividual Case Safety Reports (ICSRs) from January 1, 2016, to June 30, 2021, from the UN Asia region were included, which reported events suspected to be associated with TMs. ADRs resulting in hospital admission/prolongation of hospital stay, disability, life-threatening conditions, congenital abnormality, or death were considered serious ADRs. Demographic details, patterns of reported ADRs, and suspected TMs were analyzed along with the outcome of events.
resultsThere were 713 suspected serious ICSRs with at least one TM as a suspected drug reported, which accounted for 2.5% of the total reports. Skin and subcutaneous tissue disorders (19.8%), hepatobiliary disorders (15.3%), and gastrointestinal disorders (12.9%) were commonly reported system organ classes. Asymptomatic elevation of liver markers (8.8%) was the most common reaction, followed by vomiting (4.1%), dyspnoea (3.1%), drug-induced liver injury (3%), diarrhoea (3%), rash (2.8%), and urticaria (2.6%). Artemisia argyi (4.9%), Vitis vinifera (3.6%), Andrographis paniculata (2%), Ginkgo biloba (1.7%), Silybum marianum (1.5%), and Tinospora cordifolia (1.5%) were the most frequently suspected TMs. Seventeen (2.4%) ICSRs had a fatal outcome.
conclusionsThe present analysis revealed that various TMs have the potential to cause serious ADRs, particularly affecting the skin and subcutaneous tissue, the hepatobiliary system, and the gastrointestinal system. Their comprehensive list presented in the study will be valuable for promoting the safe use of TMs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.